- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
Patent holdings for IPC class C07D 265/30
Total number of patents in this class: 904
10-year publication summary
|
47
|
50
|
60
|
52
|
42
|
54
|
57
|
58
|
57
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10463 |
22 |
| Supernus Pharmaceuticals, Inc. | 136 |
20 |
| 3m Innovative Properties Company | 17596 |
17 |
| F. Hoffmann-La Roche AG | 7878 |
14 |
| The Regents of the University of California | 20410 |
14 |
| Corsair Pharma, Inc. | 37 |
13 |
| Hoffmann-La Roche Inc. | 3620 |
12 |
| Global Blood Therapeutics, Inc. | 178 |
12 |
| BASF SE | 21146 |
11 |
| Boehringer Ingelheim International GmbH | 4576 |
11 |
| Bristol-myers Squibb Company | 4795 |
10 |
| Allergan, Inc. | 2261 |
10 |
| Merck Sharp & Dohme LLC | 3741 |
9 |
| Glaxosmithkline LLC | 532 |
7 |
| Janssen Pharmaceutica N.V. | 3304 |
7 |
| Glaxosmithkline Intellectual Property (no.2) Limited | 304 |
7 |
| Duke University | 3161 |
7 |
| Adverio Pharma GmbH | 45 |
7 |
| Astellas Pharma Inc. | 1049 |
7 |
| Korea University Research and Business Foundation | 3125 |
7 |
| Other owners | 680 |